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antipsychotic agents to LAS treatment may be beneficial in improving treatment 
persistence in ADHD.  
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OBJECTIVES: As in many other developing countries of the world, mental health 
research in Ghana has received little attention. The epidemiology of the disease 
and the actual prevalence in the general population are virtually unknown. Few 
small scale studies have identified factors associated with depression in the 
country. Nonetheless, because of their limited scope, quality and scale of these 
studies, there remains a gap in knowledge regarding factors associated with 
depression in a general population. Therefore, the purpose of the study is to 
examine the prevalence of self-reported depression among adults (age > 18) and 
analyze the association between demographic, socio-economic, health 
conditions, and life-style practices and presence of depression in a West African 
country (Ghana) using 2002 World Health Survey. METHODS: Cross-sectional 
design was used. Data were extracted from the World Health Survey for the year 
2002. Based on an algorithm developed by Ayuso-Mateos and colleagues using 
World Health Survey, we combined depressive episode, brief episode and 
subsyndromal depression to measure presence of depression. Chi square 
statistics and logistic regressions were utilized to examine the relationship 
between self-reported depression and demographic, socio-economic, health 
conditions, and life-style practices in Ghana. RESULTS: Overall, 11.9% adults 
reported depression. Logistic regression on presence of depression revealed that 
women were more likely to have depression compared to men (AOR = 1.46, 95% 
CI = 1.13, 1.89). Among other factors, those with chronic conditions (arthritis and 
heart disease) were more likely to have depression compared to those without 
these conditions. CONCLUSIONS: This study confirms the gender differences in 
prevalence of depression. The relationship between chronic conditions and 
depression highlights the need for medical and behavioral treatment integration 
in Ghana.  
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Objective: To predict the demographic, diagnostic, comorbid, and drug 
utilization factors that may impact the likelihood of subjects initiating 
lurasidone among US employers. Methods: Analyses of administrative claims 
data from the HCMS Database comprised of multiple large geographically 
dispersed US employers from 2/1/2011(lurasidone launch) through 9/30/2012. All 
continuously enrolled subjects with a schizophrenia or bipolar disorder 
diagnosis with a prescription claim of lurasidone were classified as lurasidone 
subjects; those without a lurasidone prescription claim were controls. 
Demographics, Charlson comorbidity index (CCI) score, specific bipolar disorder 
or schizophrenia diagnoses, and use of atypical antipsychotics were described 
using means for continuous variables and proportions for categorical variables. 
Factors predicting the likelihood of initiating lurasidone were evaluated using 
stepwise logistic regression. Results: From a total of 127 lurasidone subjects and 
7754 controls, 43 lurasidone subjects (1.1%) and 3822 control subjects were 
eligible for analysis with 40.4% employees, 31.2% spouses, and 28.4% 
dependents.  The employees/spouses were 67% female, mean age 44.1 (SD=10.8) 
years and mean CCI score of 0.72 (SD=1.42). Dependents were 49% female, with 
mean age 20.7 (SD=7.4) years and mean CCI score of 0.27 (SD=0.72). The most 
commonly used atypical antipsychotics were: aripiprazole=18.6%, 
quetiapine=18.3%, risperidone=11.6%, olanzapine=6.2%, and ziprasidone=5.7%. 
Logistic regression found subjects with schizoaffective disorder (ICD-9=295.7x, 
OR=3.6, P=0.0023); use of paliperidone (OR=7.8, P<0.0001), ziprasidone (OR=5.3, 
P<0.0001), or aripiprazole (OR=2.1, P=0.0233); and younger ages (OR=0.97, 
P=0.0244) were more likely to initiate lurasidone. Conclusion: This analysis 
suggests that subjects with schizoaffective disorder and paliperidone, 
ziprasidone, aripiprazole use were >2 times as likely to take lurasidone 
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OBJECTIVES: This study examines whether mental comorbidity affects in-
hospital mortality among individuals with acute myocardial infarction (AMI). 
The present study uses nationally representative data and provides insight for 
understanding the impact of mental comorbidity on in-hospital outcomes 
among individuals with AMI. METHODS: The Nationwide Inpatient Sample (NIS) 
database of the Health Care Cost and Utilization Project (HCUP) for 2010 was 
used to identify cases where the primary diagnoses at discharge was AMI (ICD-9-
CM; 410.XX). Mental comorbidity cases were identified as discharges with 1 or 
more mental disorders (ICD-9-CM; 290.XX-319.XX) listed as the non-primary 
diagnosis. The impact of mental comorbidities on in-hospital mortality was 
evaluated using Cox proportional hazards regression. RESULTS: A total of 
232,813 cases with AMI were included in the analysis. Of these, 112,327 (48%) had 
at least one diagnosis of a mental comorbidity. According to the Cox proportional 
hazards estimation result, the presence of mental comorbidity significantly 
increases the probability of having in-hospital death (Hazard Ratio: 1.34, 95% CI: 
1.23–1.46). CONCLUSIONS: Our results suggest that mental conditions could 
increase in-hospital mortality among individuals with AMI. Whether having 
mental comorbidities is per se a risk factor for in-hospital mortality post-AMI or 
is a proxy for other unmeasured factors needs further investigation. Regardless, 
our finding suggests that presence of mental comorbidities should be accounted 
for when treating patients.  
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OBJECTIVES: This study examined, if presence of depression and/or anxiety 
confer additional risk for chronic physical conditions in the presence of obesity. 
METHODS: We used a retrospective cross-sectional study design. Study 
participants were 32,251 adults aged 22-64 years from 2007 and 2009 Medical 
Expenditure Panel Survey. Body mass index values (BMI) were used to classify 
sample adults into normal, overweight, and obese categories. Presence of 
depression and/or anxiety and BMI were combined to classify participants into 
six categories: 1) No depression and/anxiety and normal BMI;2) No depression 
and/anxiety and overweight; 3) No depression and/anxiety and obese; 4) 
Depression and/or anxiety and normal BMI; 5) Depression and/or anxiety and 
overweight; 6) Depression and/or anxiety and obese. Binary outcome variables 
indicating presence/absence of asthma, arthritis, diabetes, gastro esophageal 
reflux disease (GERD), chronic obstructive pulmonary disorder, hypertension, 
heart disease, osteoporosis, and thyroid disorders, were outcome measures. 
Exponentiated coefficients from two separate complementary log-log regressions 
were used to determine the risk of chronic physical conditions in presence 
obesity and depression and/anxiety. We tested the independent association of 
depression and/or anxiety with risk of chronic physical conditions by specifying 
two contrasts using the following reference groups ‘no depression and no 
anxiety with obesity’ and ‘no depression and no anxiety and normal BMI’ in two 
separate regression models. RESULTS: Among individuals with obesity, those 
with depression and/or anxiety were at higher risk of having chronic physical 
conditions (except osteoporosis) compared to individuals with no depression and 
no anxiety. The Adjusted Risk Ratios (ARRs) ranged from 2.07 (95% CI: 1.73, 2.48) 
for GERD to 1.29 (95%CI: 1.07, 1.56) for asthma. Among individuals with normal 
BMI, those with depression and/or anxiety were at higher risk of having chronic 
physical conditions compared to individuals with no depression and no anxiety. 
The ARRs ranged from 2.30 (95%CI: 1.69, 3.13) for GERD to 1.44 (95%CI: 1.22, 1.69) 
for arthritis. CONCLUSIONS: Presence of depression and/or anxiety conferred an 
independent risk for having chronic physical conditions after regardless of BMI 
categories.  
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OBJECTIVES: To estimate the budget impact of the inclusion of quetiapine 
compared to aripiprazole or olanzapine on the top of standard bipolar disorder 
treatment scheme with atypical antipsychotics according to Russian health care 
system. METHODS: The one year budget impact analysis was conducted. Direct 
expenses associated with bipolar disorder and resulting follow-up costs were 
calculated using general tariff agreement of Russian obligatory insurance system 
and official national statistics. For reference, accepted exchange rate was 1 EUR = 
40 RUB. RESULTS: Quetiapine inclusion into the standard bipolar disorder 
therapy provided cost saving benefits compared with inclusion of aripiprazole or 
olanzapine in the bipolar disorder standard therapy scheme. Total health care 
costs of bipolar disorder therapy were approximately 396 539 RUB (9,913 EUR) per 
patient in quetiapine group, 1,023 089 RUB (25,577 EUR) per patient in 
aripiprazole group and 557,222 RUB (13,931 EUR) per patient in olanzapine group 
within one year. Treatment of bipolar disorder using standard therapy with 
quetiapine inclusion compared to one with aripiprazole or olanzapine leads to 
cost savings of 626,551 RUB (15,664 EUR) or 160,683 RUB (4,017 EUR) per patient-
year, respectively. CONCLUSIONS: The results of budget impact analysis 
illustrate that including quetiapine into the standard therapy of bipolar disorder 
in comparison with aripiprazole or olanzapine has potential to reduce Russian 
health care system total costs for bipolar disorder treatment.  
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